These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 1914846

  • 21. [A new therapeutic proposal for intermittent claudication. Propionyl-L-carnitine: new indications concerning mechanism of action].
    Brevetti G, Martone VD, Corrado S, Silvestro A, Di Donato AM, Di Iorio A.
    Minerva Cardioangiol; 1998 Sep; 46(9):299-300. PubMed ID: 10021852
    [No Abstract] [Full Text] [Related]

  • 22. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B.
    Ren Fail; 2005 Sep; 27(4):367-72. PubMed ID: 16060121
    [Abstract] [Full Text] [Related]

  • 23. Blood viscosity and red cell morphology in subjects suffering from cirrhosis before and after treatment with S-adenosyl-L-methionine (SAM).
    Turchetti V, Bellini MA, Leoncini F, Petri F, Trabalzini L, Guerrini M, Forconi S.
    Clin Hemorheol Microcirc; 2000 Sep; 22(3):215-21. PubMed ID: 10976715
    [Abstract] [Full Text] [Related]

  • 24. [Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis].
    Kalinowski M, Popławski A, Mazerska M, Daniluk A.
    Pol Merkur Lekarski; 1999 Feb; 6(32):76-8. PubMed ID: 10337176
    [Abstract] [Full Text] [Related]

  • 25. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure.
    Thompson CH, Irish AB, Kemp GJ, Taylor DJ, Radda GK.
    Clin Nephrol; 1997 Jun; 47(6):372-8. PubMed ID: 9202867
    [Abstract] [Full Text] [Related]

  • 26. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A.
    Ann Vasc Surg; 2008 Jun; 22(4):552-8. PubMed ID: 18502605
    [Abstract] [Full Text] [Related]

  • 27. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases.
    Feher G, Koltai K, Kesmarky G, Horvath B, Toth K, Komoly S, Szapary L.
    Phytomedicine; 2009 Mar; 16(2-3):111-7. PubMed ID: 19135345
    [Abstract] [Full Text] [Related]

  • 28. L-carnitine could not improve hepatic warm ischemia-reperfusion injury despite ameliorated blood flow.
    Yonezawa K, Tolba RH, Wetter A, Yamamoto Y, Yamaoka Y, Minor T.
    J Surg Res; 2005 May 01; 125(1):16-22. PubMed ID: 15836845
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo.
    Coto V, D'Alessandro L, Grattarola G, Imparato L, Lingetti M, Mancini M, Nolfe G, Rengo F.
    Drugs Exp Clin Res; 1992 May 01; 18(1):29-36. PubMed ID: 1600865
    [Abstract] [Full Text] [Related]

  • 30. L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis.
    Perna AF, Acanfora F, Satta E, Lombardi C, Capasso R, Ingrosso D, De Santo NG.
    J Nephrol; 2007 May 01; 20(1):63-5. PubMed ID: 17347975
    [Abstract] [Full Text] [Related]

  • 31. Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus.
    Al-Majed AA, Sayed-Ahmed MM, Al-Omar FA, Al-Yahya AA, Aleisa AM, Al-Shabanah OA.
    Clin Exp Pharmacol Physiol; 2006 Aug 01; 33(8):725-33. PubMed ID: 16895547
    [Abstract] [Full Text] [Related]

  • 32. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products.
    Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, Herrera MD.
    Life Sci; 2005 Sep 09; 77(17):2082-97. PubMed ID: 15958269
    [Abstract] [Full Text] [Related]

  • 33. [Effect of molsidomine on rheological parameters and the incidence of cardiovascular events].
    Wöhrle J, Nusser T, Hoffmeister A, Kestler HA, Grebe OC, Höher M, Hombach V, Koenig W, Kochs M.
    Dtsch Med Wochenschr; 2003 Jun 13; 128(24):1333-7. PubMed ID: 12802741
    [Abstract] [Full Text] [Related]

  • 34. [Whole blood filterability in chronic cerebrovascular disorders: effects of the use of buflomedil hydrochloride].
    Ciuffetti G, Mercuri M, Lombardini R, Palazzetti D, Rizzo MT, Parnetti L.
    Minerva Med; 1989 Nov 13; 80(11):1237-40. PubMed ID: 2689916
    [Abstract] [Full Text] [Related]

  • 35. Thrombosis induced by endothelin (ET-1) and carrageenin in rats treated with indomethacin and propionyl carnitine.
    Bertelli A, Bertelli AA, Galmozzi G, Giovannini L, Mian M.
    Drugs Exp Clin Res; 1993 Nov 13; 19(2):75-8. PubMed ID: 8223146
    [Abstract] [Full Text] [Related]

  • 36. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1999 Feb 13; 469():1-361. PubMed ID: 12579204
    [Abstract] [Full Text] [Related]

  • 37. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease.
    Bolognesi M, Amodio P, Merkel C, Godi L, Gatta A.
    Clin Physiol; 1995 Sep 13; 15(5):417-23. PubMed ID: 8846662
    [Abstract] [Full Text] [Related]

  • 38. Our experience with the use of buflomedil chlorhydrate in a mixed population of vasculopathic patients.
    Battaglia L, Valgiusti D, Di Paola FM.
    J Int Med Res; 1984 Sep 13; 12(2):63-72. PubMed ID: 6724128
    [Abstract] [Full Text] [Related]

  • 39. Propionyl-L-carnitine.
    Wiseman LR, Brogden RN.
    Drugs Aging; 1998 Mar 13; 12(3):243-8; discussion 249-50. PubMed ID: 9534023
    [Abstract] [Full Text] [Related]

  • 40. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis.
    Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri Conti G, Fallico R, Di Pino L, Pennisi G, Celotta G, Massimiliano A.
    Drugs Aging; 2006 Mar 13; 23(3):263-70. PubMed ID: 16608381
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.